Viemed Healthcare Inc

Viemed Healthcare Inc(VMD)の株式分析

$9.670

-0.272 (-2.81%)終値時点

Loading chart…
高値
10.025
始値
10.000
出来高加重平均価格
9.78
出来高
119.53K
時価総額
251.17M
安値
9.632
売買代金
1.17M
EV/EBITDA(TTM)
7.15

Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services.

www.viemed.com

AI分析 of Viemed Healthcare Inc (VMD)

買い

Viemed Healthcare Inc is a good buy right now due to its current price of $9.80, which is significantly below the analyst price target of $14. The company has shown strong revenue growth, with Q2 revenue of $78.1 million, a 23.7% increase year-over-year, and a gross margin of 57.7%. However, the main risk is the earnings miss in the last report, where EPS was $0.07 compared to the expected $0.10, indicating potential profitability pressures.

バリュエーション指標

Viemed Healthcare Inc(VMD)の現在の予想PERは24.39で、5年平均は23.93です。

予想PER

適正
5年平均 P/E
23.93
現在のP/E
24.39
割高
30.94
割安
16.93

予想EV/EBITDA

適正
5年平均 EV/EBITDA
6.05
現在のEV/EBITDA
7.15
割高
7.37
割安
4.72

予想PSR

適正
5年平均 P/S
1.31
現在のP/S
1.07
割高
1.64
割安
0.98

Alphio AI による VMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%VMD

$9.49

シナリオ価格

基

基本

基本 · 50%VMD

$8.88

シナリオ価格

弱

弱気

弱気 · 25%VMD

$7.16

シナリオ価格

イベントタイムライン

2026-03-04 (ET)

16:50:00

Viemed Healthcare Authorizes Share Repurchase Program Through March 2027

2025-07-02 (ET)

08:43:56

Viemed Healthcare completes acquisition of Lehan's Medical Equipment

2025-06-09 (ET)

08:18:09

Viemed Healthcare board authorizes share repurchase program up to 5%

2025-05-06 (ET)

08:32:47

Viemed entered into definitive agreement to acquire Lehan's Medical Equipment

2025-03-10 (ET)

17:02:06

Viemed Healthcare sees FY25 revenue $254M-$265M, consensus $251.43M

ニュース

VMD のよくある質問 — Alphio AI が回答

Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Viemed Healthcare Inc is a good buy right now due to its current price of $9.80, which is significantly below the analyst price target of $14. The company has shown strong revenue growth, with Q2 revenue of $78.1 million, a 23.7% increase year-over-year, and a gross margin of 57.7%. However, the main risk is the earnings miss in the last report, where EPS was $0.07 compared to the expected $0.10, indicating potential profitability pressures.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める